ERA-EDTA Symposium 2018

Read story

ESC Congress 2017

Read story

ERA-EDTA Congress 2017

Read story

ESC Congress 2016

Read story

EASD 2016

Read story

European Biopharmaceutical Review

Read story

New York Academy of Science Symposium

Read story

The Complement System: Part 1

Read story

The Complement System: Part 2

Read story

The Complement System: Part 3

Read story

Diabetes Mellitus

Read story

Chronic Kidney Disease

Read story

The New Frontier of Epigenetics

Read story

Readers, Writers & Erasers in Epigenetics

Read story

Clinical Trials Series: Part 1

Read story

Clinical Trials Series: Part 2

Read story

Clinical Trials Series: Part 3

Read story

Pharmacoeconomics

Read story

Sanofi Biogenius Competition CTV News feature

Read story

World Diabetes Day

Read story

ESC Congress 2016

Resverlogix supported a PACE-CME educational symposium on Epigenetics at the European Society of Cardiology (ESC) Congress 2016, titled: “A Novel Approach for High CV Risk Patients with Diabetes: The Potential of Epigenetics,” featuring Key Opinion Leaders in cardiovascular disease and diabetes.

Featured presenters included:

Prof. Kausik Ray, Imperial College, London, UK: The high risk diabetes patient with cardiovascular disease: What else can we target to reduce cardiovascular risk?

Dr. Jorge Plutzky, Brigham and Woman’s Hospital, Harvard Medical School, Boston, MA: Understanding BET inhibition as a novel pathway for cardiovascular risk modulation. 

Prof. John Kastelein, Academic Medical Center, Amsterdam, Netherlands: BET inhibition in cardiovascular disease: A new dawn?

Meeting Highlights, Videos and Slides from the symposium can be accessed HERE.